Want to see CCCC full AI Analyst Report?
Top Page
C4 Therapeutics
(NASDAQ:CCCC)
Select Model
Select Model
Rating:60Neutral
Price Target:
$3.50
▲(2.94% Upside)
Action:Reiterated
Date:07/01/26
The score is held back primarily by weak financial performance (large losses and cash burn), partially offset by a strong technical uptrend (price above all major moving averages) and positive corporate developments (Roche collaboration and clinical progress). Valuation is constrained by the negative P/E, reflecting unprofitable operations.
Positive Factors
Platform & Pipeline
C4's TORPEDO platform is a structural competitive advantage: a proprietary discovery engine for small-molecule degraders that can be applied across oncology and other indications. This platform-driven model supports repeatable program generation, partner licensing, and long-term pipeline value independent of short-term results.
Negative Factors
High Cash Burn
Sustained negative operating and free cash flow near -$95M TTM is a durable structural weakness: it forces reliance on partnerships, milestones, or new financings to sustain operations. Prolonged cash burn can pressure R&D prioritization, increase dilution risk, and constrain strategic optionality if clinical timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & Pipeline
C4's TORPEDO platform is a structural competitive advantage: a proprietary discovery engine for small-molecule degraders that can be applied across oncology and other indications. This platform-driven model supports repeatable program generation, partner licensing, and long-term pipeline value independent of short-term results.
Read all positive factors
C4 Therapeutics (CCCC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$392.51M
Dividend YieldN/A
Average Volume (3M)3.60M
Price to Earnings (P/E)―
Beta (1Y)2.48
Revenue Growth-12.37%
EPS Growth19.59%
CountryUS
Employees104
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.19
Shares Outstanding110,567,220
10 Day Avg. Volume2,926,881
30 Day Avg. Volume3,597,566
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside150.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$23.18M
C4 Therapeutics Business Overview & Revenue Model
Company Description
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions incl...
How the Company Makes Money
C4 Therapeutics primarily generates revenue through collaboration and license agreements with larger pharmaceutical companies, rather than through product sales (as it is clinical-stage). Under these arrangements, the company can earn (1) upfront ...
C4 Therapeutics Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
63
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.86M | 35.95M | 35.58M | 20.76M | 31.10M | 45.78M |
| Gross Profit | 33.06M | 27.97M | 35.58M | 13.02M | 31.10M | 45.78M |
| EBITDA | -100.38M | -102.91M | -103.37M | -122.10M | -124.28M | -80.25M |
| Net Income | -103.80M | -104.99M | -105.32M | -132.49M | -128.18M | -83.89M |
Balance Sheet | ||||||
| Total Assets | 328.86M | 359.07M | 349.60M | 376.45M | 430.84M | 506.76M |
| Cash, Cash Equivalents and Short-Term Investments | 235.67M | 248.54M | 244.90M | 253.68M | 276.15M | 309.28M |
| Total Debt | 58.45M | 59.98M | 65.76M | 70.98M | 87.15M | 42.88M |
| Total Liabilities | 94.61M | 102.49M | 133.62M | 130.34M | 141.61M | 117.16M |
| Stockholders Equity | 234.25M | 256.59M | 215.99M | 246.11M | 289.23M | 389.61M |
Cash Flow | ||||||
| Free Cash Flow | -96.02M | -99.30M | -65.34M | -108.55M | -111.44M | -88.24M |
| Operating Cash Flow | -95.35M | -98.69M | -65.16M | -106.84M | -105.94M | -86.97M |
| Investing Cash Flow | -21.57M | -8.60M | -51.27M | 158.35M | 58.42M | -189.34M |
| Financing Cash Flow | 126.91M | 126.40M | 45.34M | 45.49M | 1.15M | 171.40M |
C4 Therapeutics Technical Analysis
Negative
3.40
Price Trends
3.90
Negative
3.39
Positive
2.84
Positive
Market Momentum
-0.11
Positive
37.91
Neutral
23.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Negative. The current price of 3.4 is below the 20-day moving average (MA) of 3.87, below the 50-day MA of 3.90, and above the 200-day MA of 2.84, indicating a neutral trend. The MACD of -0.11 indicates Positive momentum. The RSI at 37.91 is Neutral, neither overbought nor oversold. The STOCH value of 23.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCCC.
C4 Therapeutics Risk Analysis
C4 Therapeutics disclosed 73 risk factors in its most recent earnings report. C4 Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
C4 Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $392.51M | -2.98 | -50.68% | ― | -12.37% | 19.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $262.44M | -3.91 | -96.80% | ― | ― | -1.48% | |
47 Neutral | $1.88B | -44.20 | -47.12% | ― | ― | 41.60% | |
42 Neutral | $46.48M | -0.93 | -127.30% | ― | ― | 49.74% | |
41 Neutral | $35.87M | -0.96 | 241.39% | ― | ― | 38.95% |
* Healthcare Sector Average
CCCC
C4 Therapeutics
3.52
1.36
62.96%
SLS
SELLAS Life Sciences Group
10.10
8.44
508.43%
MCRB
Seres Therapeutics
4.65
-9.75
-67.71%
ELDN
Eledon Pharmaceuticals
3.31
0.15
4.75%
TVGN
Tevogen Bio Holdings
5.94
-45.06
-88.35%
ACTU
Actuate Therapeutics, Inc.
1.08
-6.19
-85.14%
C4 Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
C4 Therapeutics Shareholders Back Directors, Pay and Auditors
Positive
Jun 24, 2026
On June 24, 2026, C4 Therapeutics, Inc. held its Annual Meeting of Stockholders, at which shareholders elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors to serve until the 2029 annual meeting. Stockholders ...
Business Operations and Strategy
C4 Therapeutics Highlights Cemsidomide Strategy and Trial Progress
Positive
Jun 11, 2026
On June 11, 2026, C4 Therapeutics posted a new corporate presentation detailing its strategic focus on best-in-class and first-in-class targeted protein degraders, highlighting cemsidomide for multiple myeloma and its discovery work in inflammatio...
Business Operations and StrategyExecutive/Board Changes
C4 Therapeutics Realigns Finance Leadership After Officer Departure
Neutral
May 15, 2026
C4 Therapeutics, Inc. announced that on May 12, 2026, it decided Chief Accounting Officer Mark Mossler will leave his role effective May 15, 2026, with the company stating his departure is not related to any disagreement over financial reporting, ...
Business Operations and StrategyFinancial Disclosures
C4 Therapeutics Reports Q1 Results and Clinical Advancements
Positive
May 12, 2026
On May 12, 2026, C4 Therapeutics reported first-quarter 2026 results and highlighted clinical progress, including dosing first patients in its Phase 2 MOMENTUM trial and a Phase 1b trial combining cemsidomide, dexamethasone and elranatamab for mul...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.